Ventyx Biosciences (VTYX)

• Market cap: $586M
• 1 day: -1.56%
• 5 days: -3.41%
• 1 month: -13.58%
• 3 months: 252.36%
• 6 months: 223.23%
• Year to date: 283.64%
• 1 year: 264.89%
• 5 years: -60.94%
• 10 years: -60.94%
• Sector: Healthcare
• Industry: Biotechnology

About: Ventyx Biosciences Inc is a clinical-stage biopharmaceutical company focused on advancing new therapies for millions of patients living with inflammatory diseases and autoimmune, and neurodegenerative disorders. The company is developing a pipeline of novel small-molecule product candidates to address a range of inflammatory diseases. Its product candidate VTX958 is an oral, selective clinical-stage tyrosine kinase type 2 (TYK2) inhibitor designed to inhibit TYK2 without detectable inhibition of other Janus kinase (JAK) isoforms, which avoids toxicities associated with broader JAK inhibition and, thus, other JAK inhibitors.

Employees: 81